This article is more than 5 years old. Information may no longer be current.

Patients report similar preference between two different hyaluronic acid fillers

Two hyaluronic acid fillers for the treatment of moderate nasolabial folds had no significant difference in subject preference and were effective and safe, according to study results published in Dermatologic Surgery.

The researchers compared the outcomes of Restylane Refyne, previously Emervel Classic (Galderma SA, Lausanne, Switzerland) and Restylane (Q-Med AB, Uppsala, Sweden) in treating moderate nasolabial folds. The effectiveness was assessed using the Wrinkle Severity Rating Scale (scores increasing in severity from 1 to 5) and patient preference at final follow-up.

Eighty-one patients were enrolled between Apr. 17, 2009, and Dec. 1, 2010. Sixty-eight patients completed the full study. Mean patient age was 51 years (range, 25-77). Each patient was randomly injected with a similar volume of each product on either the left or right side of the face. Retreatment was administered at 9 months with final follow-up at 18 months.

The mean change from baseline Wrinkle Severity Rating Scale at 9 months was 0.68 for Restylane Refyne and 0.6 for Restylane. Following retreatment at 9 months, the mean change was 0.93 for Restylane Refyne and 0.95 for Restylane.

At 18 months follow-up, 53 patients indicated an interest in a final retreatment. Thirty-two of the patients preferred the side that was treated with Restylane Refyne while 21 preferred the Restylane. There was no statistically significant difference in subject preference.

All treatment-related adverse events were mild and resolved within a month, except for one event of telangiectasia occurring on the side with Restylane, which continued to the end of the study. The event was assessed as mild and did not need treatment. – by Talitha Bennett

Disclosure: Rzany reports he is an advisor for Merz and received provisions from Galderma for use in the study including a camera, the investigational products, and reimbursement for the cost of subject participation. Please see the full study for the other researchers’ relevant financial disclosures.